☆ 4.0 Article

The Influence of Pre-Existing Immunity against Human Common Cold Coronaviruses on COVID-19 Susceptibility and Severity

MICROBIOLOGY RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Virology

Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination

Fatima Amanat et al.

Summary: Seasonal coronaviruses have been circulating widely in the human population and it has been hypothesized that immunity to these viruses may provide partial protection against SARS-CoV-2 infection. COVID-19 vaccination has also been shown to boost immunity against seasonal betacoronaviruses.

JOURNAL OF VIROLOGY (2023)

添加到收藏夹

Article Immunology

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination

Di Yin et al.

Summary: A study in China found that pre-existing cross-reactive immunity among different coronaviruses may have an impact on subsequent SARS-CoV-2 infection and COVID-19 vaccination effectiveness. However, it was observed that pre-existing antibodies against seasonal coronaviruses did not significantly affect the immunogenicity of COVID-19 vaccines.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Microbiology

Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response

Chun-Yang Lin et al.

Summary: This study found that prior immunity to common cold coronaviruses does not affect protection against SARS-CoV-2 infection. Instead, higher levels of pre-existing betacoronavirus antibodies are associated with more severe disease following SARS-CoV-2 infection. Additionally, immunization with common cold coronavirus spike proteins hinders the generation of SARS-CoV-2 neutralizing antibodies.

CELL HOST & MICROBE (2022)

添加到收藏夹

Article Virology

Humoral response to SARS-CoV-2 and seasonal coronaviruses in COVID-19 patients

Ortwin Adams et al.

Summary: The study found that COVID-19 patients had relatively higher antibody levels against four seasonal human coronaviruses, with only slight elevation in levels for HCoV-HKU1 and HCoV-229E; Antibody levels against SARS-CoV-2 were significantly correlated with disease severity, while no association was found for antibodies against seasonal human coronaviruses.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Immunology

Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation

Makoto Miyara et al.

Summary: It was found that most COVID-19 patients developed IgG antibodies against SARS-CoV-2, as well as IgG antibodies against beta-HCoV. However, pre-existing immunity to HCoV does not provide cross-protection against COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Cell Biology

SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations

Elizabeth M. Anderson et al.

Summary: The study found that SARS-CoV-2 infections and mRNA vaccinations elicit fundamentally different antibody responses. Infection and initial vaccination produce S1 and S2 reactive antibodies, while secondary vaccination mainly enhances S1 antibodies. The research also revealed that infections generate a large proportion of antibodies with efficient binding to the spike protein of common seasonal human coronaviruses but poor binding to the spike protein of SARS-CoV-2, whereas vaccination boosts antibodies that react to the spike protein of common seasonal human coronaviruses and cross-react more efficiently to the spike protein of SARS-CoV-2.

CELL REPORTS (2022)

添加到收藏夹

Article Immunology

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination

Caiqin Hu et al.

Summary: This study aimed to investigate whether prior immunity to seasonal human coronaviruses (HCoVs) could affect the immune response induced by the SARS-CoV-2 vaccine. The study found that prior antibodies to seasonal HCoVs existed and could be boosted by the SARS-CoV-2 vaccine. Specifically, HCoV-OC43 antibodies were associated with protective immunity to SARS-CoV-2, supporting the development of a pan-coronavirus vaccine.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

添加到收藏夹

Review Cell Biology

Aging in COVID-19: Vulnerability, immunity and intervention

Yiyin Chen et al.

Summary: The COVID-19 pandemic originating from Wuhan in December 2019 has had far-reaching health and socioeconomic impacts worldwide. The disease caused by SARS-CoV-2 is highly heterogeneous, with age, gender, and comorbidities playing key roles in disease severity and outcomes. Aging and dysregulation of immune function are thought to contribute to the increased vulnerability of older adults to severe COVID-19. Further research on immune responses to SARS-CoV-2 infection, particularly in different age groups, is crucial for understanding disease heterogeneity and developing effective vaccines.

AGEING RESEARCH REVIEWS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.

CELL (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Recent endemic coronavirus infection is associated with less-severe COVID-19

Manish Sagar et al.

Summary: The study suggests that individuals with prior endemic coronavirus infections were tested more frequently for respiratory infections, but had similar rates of acquiring SARS-CoV-2. Additionally, patients with previous endemic coronavirus infections experienced less severe cases of COVID-19.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Infectious Diseases

Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities

Kazuo Imai et al.

Summary: The study found that there was no significant association between the antibody titer for seasonal HCoVs in the early phase of COVID-19 and disease severity; however, significant increases in antibody titers for HCoV-HKU1 and -OC43 IgG-S, as well as for HCoV-NL63 and -229E IgG-N, were observed during convalescence in severe cases.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medical Laboratory Technology

Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies

Carlota Dobano et al.

Summary: The study found that the nucleocapsid (N) protein of SARS-CoV-2 is a primary target of immune response in COVID-19 patients, with potential crossreactivity with common cold human coronaviruses. A region with minimal sequence homology with HCoV in the SARS-CoV-2 N protein was identified, showing higher specificity and immunogenicity. Higher levels of antibodies to SARS-CoV-2 N were observed in patients with more severe symptoms, longer duration of illness, and in females.

TRANSLATIONAL RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

Matthias Becker et al.

Summary: The humoral immune response to SARS-CoV-2 is crucial for understanding COVID-19 progression, monitoring seroconversion, and supporting vaccine development. A multiplex immunoassay has been developed, including spike and nucleocapsid proteins of SARS-CoV-2 and endemic human coronaviruses, with high specificity and sensitivity.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Cell Biology

Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses

Paul R. Wratil et al.

Summary: Studies suggest that pre-existing immune responses to seasonal coronaviruses may increase susceptibility to SARS-CoV-2 and predispose individuals to adverse COVID-19 outcomes. This finding has important implications for risk management and the development of universal coronavirus vaccines.

CELL REPORTS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles

Elizabeth R. Lusczek et al.

Summary: This study identified three clinical phenotypes of COVID-19, reflecting different patient populations with varying comorbidities, complications, and clinical outcomes. Further research is needed to determine the utility of these phenotypes in clinical practice and trial design.

PLOS ONE (2021)

添加到收藏夹

Article Infectious Diseases

SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection

Saurabh Gombar et al.

Summary: The study shows that individuals with a history of seasonal coronavirus infection have similar rates of SARS-CoV-2 infection and severity of COVID-19 compared to those without such a history, indicating that prior infection with seasonal coronaviruses does not confer immunity to subsequent infection with SARS-CoV-2.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)

添加到收藏夹

Article Virology

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Martin Dugas et al.

Summary: The study analyzed the importance of seroreactivity against seasonal human coronaviruses in COVID-19 patients and found that patients who were OC43 negative were more likely to develop critical illness. A risk stratification based on sex and OC43 serostatus proved to be useful in predicting critical disease progression.

JOURNAL OF CLINICAL VIROLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Natalia Ortega et al.

Summary: Long-term kinetics of antibodies to SARS-CoV-2 were examined in a cohort of health care workers, showing stable levels over time with an increase in anti-spike antibody levels around 150 days post-symptom onset. Additionally, asymptomatic individuals had significantly higher levels of IgG and IgA to HCoV compared to symptomatic individuals, suggesting a potential protective effect of pre-existing cross-reactive HCoVs antibodies against SARS-CoV-2 infection and COVID-19 disease.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunological imprinting of the antibody response in COVID-19 patients

Teresa Aydillo et al.

Summary: The study found that previous infections with seasonal coronaviruses can affect the antibody response to SARS-CoV-2 in COVID-19 patients. While SARS-CoV-2 infection can boost pre-existing responses to other coronaviruses, this back-boosting hampers the induction of specific antibodies against SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration

Sigrid Gouma et al.

Summary: Recent studies suggest that common coronavirus infections may reduce the severity of COVID-19 upon SARS-CoV-2 infection. Individuals with higher beta coronavirus antibody titers experienced significantly reduced symptom duration following SARS-CoV-2 infection. While cross-reactive antibodies elicited by past infections do not provide protection, cellular immune responses may transiently reduce symptom duration.

JCI INSIGHT (2021)

添加到收藏夹

Review Microbiology

Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study

Robert E. Sealy et al.

Summary: The study explores cross-reactive immune responses between SARS-CoV-2 and common cold coronaviruses, finding cross-reactive antibodies in SARS-CoV-2-unexposed humans but limited specific antibody responses to SARS-CoV-2. Meanwhile, individuals who have been exposed to common cold HCoVs may receive some level of protection against SARS-CoV-2 infection.

MICROORGANISMS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19

Muriel Aguilar-Bretones et al.

Summary: The study found different IgG responses to SARS-CoV-2 and seasonal coronaviruses in COVID-19 patients, with boosted IgG clones against seasonal coronaviruses in severe patients, which did not neutralize SARS-CoV-2.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Cell Biology

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Kristen W. Cohen et al.

Summary: The study reveals that COVID-19 patients have durable broad-based immune responses, including the continuous generation of antibodies, memory B cells, and polyfunctional T cells, which help to rapidly generate antibody responses against virus re-exposure or vaccination.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Cell Biology

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses

Jason T. Ladner et al.

Summary: The study used a highly multiplexed peptide assay to investigate antibody responses across all human coronaviruses in COVID-19 convalescent and negative donors. The results show that antibodies elicited by SARS-CoV-2 can cross-recognize specific epitopes of pandemic and endemic coronavirus antigens, with a preference for binding endemic homologs.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Immunology

Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study

Li Guo et al.

Summary: This study revealed that there is a cross-reactivity between antibodies against seasonal human coronaviruses and SARS-CoV-2 in COVID-19 patients. Specifically, higher levels of HCoV-OC43 antibodies were found to be associated with disease severity in COVID-19 patients.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Immunology

Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Lisa Henss et al.

Summary: The study found that the severity of COVID-19 is correlated with patient age, gender, the amount of SARS-CoV-2-specific antibodies, and their neutralization activity. The levels of specific antibodies decrease over time, with faster decline in nucleoprotein antibodies. NL63 neutralizing activities are associated with COVID-19 severity, suggesting potential cross-reactive protection.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Virology

Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV

Jiabao Xu et al.

VIRUSES-BASEL (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Jian-Min Jin et al.

FRONTIERS IN PUBLIC HEALTH (2020)

添加到收藏夹

Article Immunology

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Lakshmanane Premkumar et al.

SCIENCE IMMUNOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Ahmad Abu Turab Naqvi et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Anna Z. Wec et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Ellen Shrock et al.

SCIENCE (2020)

添加到收藏夹

Article Microbiology

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

Phuong Nguyen-Contant et al.

MBIO (2020)

添加到收藏夹

Article Microbiology

Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity

Carolin Loos et al.

MSPHERE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63

Giulietta Saletti et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Kevin W. Ng et al.

SCIENCE (2020)

添加到收藏夹

Article Cell Biology

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Jeremie Prevost et al.

CELL REPORTS MEDICINE (2020)

添加到收藏夹

Letter Infectious Diseases

Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection

Xin Gao et al.

JOURNAL OF INFECTION (2015)

添加到收藏夹

Article Immunology

Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in Serum

Geoffrey J. Gorse et al.

CLINICAL AND VACCINE IMMUNOLOGY (2010)

添加到收藏夹

Review Infectious Diseases

Identification of new human coronaviruses

Krzysztof Pyrc et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)

添加到收藏夹

Article Immunology

Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children

F Esper et al.

JOURNAL OF INFECTIOUS DISEASES (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.